Pembrolizumab
Brand: Keytruda (global)
Anticancer
PD-1 Immune Checkpoint Inhibitor
Pharmacokinetics
| Half-life | 528 hours |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | RAW70 historical: 2 mg/kg q3wk ≈ 140 mg. Current standard: 200 mg fixed q3wk. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, thyroid dysfunction
Contraindications:
Severe autoimmune disease
Precautions:
Monitor thyroid, liver, adrenal; treat severe immune AEs with steroids
alf-life ~22 days → 22×24 = 528 hours
dose usual: 200 mg once every 3 weeks
= approx ** ≈ 9.52 mg/day average**
BUT dosing pattern is fixed 200 mg q21 days
so we store raw mg/kg info and RAW70 logic:
200 mg fixed dosing is NOT weight based.
but old trials = 2 mg/kg every 3 weeks (for 70 kg ≈ 140 mg)
now standard = 200 mg fixed dose.